temozolomide has been researched along with Carcinoma, Neuroendocrine in 12 studies
Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) has been successfully used to treat a variety of malignancies, such as glioblastoma multiforme, astrocytoma, non-small-cell lung carcinoma." | 1.48 | Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report. ( Dong, XF; Hu, ZL; Lu, YF; Tang, S; Wei, J, 2018) |
| " According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m(2)/day-one-week-on/on-week-off)." | 1.43 | Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. ( Arcella, A; Ascierto, PA; Cicala, D; De Divitiis, C; Grimaldi, AM; Iaffaioli, RV; Romano, GM; Simeone, E; Tafuto, S; Tatangelo, F; von Arx, C, 2016) |
| "Necrolytic migratory erythema is an obligatory paraneoplastic syndrome." | 1.39 | Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. ( Enk, AH; Gronau, M; Hassel, JC; Jäger, D, 2013) |
| "Treatment with temozolomide alone or in combination with capecitabine and bevacizumab resulted in objective response or stabilization in 71% of PDEC patients who failed on first-line chemotherapy." | 1.37 | Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. ( Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hiddinga, B | 1 |
| Zwaenepoel, K | 1 |
| Janssens, A | 1 |
| Van Meerbeeck, J | 1 |
| Pauwels, P | 1 |
| Ørting, AM | 1 |
| Clausen, MM | 1 |
| Soldath, P | 1 |
| Petersen, RH | 1 |
| Knigge, U | 1 |
| Andreassen, M | 1 |
| Kjær, A | 1 |
| Langer, SW | 1 |
| Nakano-Tateno, T | 1 |
| Satou, M | 1 |
| Inoshita, N | 1 |
| van Landeghem, FKH | 1 |
| Easaw, J | 1 |
| Mehta, V | 1 |
| Tateno, T | 1 |
| Chik, CL | 1 |
| Kobayashi, N | 1 |
| Takeda, Y | 1 |
| Okubo, N | 1 |
| Suzuki, A | 1 |
| Tokuhisa, M | 1 |
| Hiroshima, Y | 1 |
| Ichikawa, Y | 1 |
| Wei, J | 1 |
| Dong, XF | 1 |
| Hu, ZL | 1 |
| Tang, S | 1 |
| Lu, YF | 1 |
| Rogowski, W | 1 |
| Wachuła, E | 1 |
| Gorzelak, A | 1 |
| Lebiedzińska, A | 1 |
| Sulżyc-Bielicka, V | 1 |
| Iżycka-Świeszewska, E | 1 |
| Żołnierek, J | 1 |
| Kos-Kudła, B | 1 |
| De Divitiis, C | 1 |
| von Arx, C | 1 |
| Grimaldi, AM | 1 |
| Cicala, D | 1 |
| Tatangelo, F | 1 |
| Arcella, A | 1 |
| Romano, GM | 1 |
| Simeone, E | 1 |
| Iaffaioli, RV | 1 |
| Ascierto, PA | 1 |
| Tafuto, S | 1 |
| Lindholm, DP | 1 |
| Eriksson, B | 1 |
| Granberg, D | 2 |
| Welin, S | 2 |
| Sorbye, H | 1 |
| Sebjornsen, S | 1 |
| Knappskog, S | 1 |
| Busch, C | 1 |
| Oberg, K | 2 |
| Crona, J | 1 |
| Björklund, P | 1 |
| Kozlovacki, G | 1 |
| Gronau, M | 1 |
| Jäger, D | 1 |
| Enk, AH | 1 |
| Hassel, JC | 1 |
| Gounaris, I | 1 |
| Rahamim, J | 1 |
| Shivasankar, S | 1 |
| Earl, S | 1 |
| Lyons, B | 1 |
| Yiannakis, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for temozolomide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
11 other studies available for temozolomide and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Topics: Anaplastic Lymphoma Kinase; Biomarkers; Carcinoid Tumor; Carcinoma, Neuroendocrine; DNA; DNA Methyla | 2022 |
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide.
Topics: Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Dacarbazine; Humans; Lung Neoplasms; Neuroendocrin | 2023 |
Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Corticotrop | 2021 |
Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; H | 2018 |
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine | 2019 |
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Administration, Metronomic; Animals; Carcinoma, Neuroendocrine; Cell Differentiation; Dacarbazine; F | 2016 |
Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2012 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Neuroendo | 2013 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neur | 2013 |
Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Ci | 2007 |